Press Releases Daewoong Pharmaceutical Co., Ltd

Equities

A069620

KR7069620003

End-of-day quote Korea S.E. Other stock markets 03:30:00 13/05/2024 am IST			5-day change	1st Jan Change
1,09,700 ^KRW	-0.90%		-1.97%	-6.08%

24/04	Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	MT
12/04	AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daewoong Pharmaceutical : and Zydus Announce Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S.	11/12	PU
Daewoong Pharmaceutical : Strikes a $60 Million Deal with JSC Pharmasyntez for Diabetes Novel Drug Enavogliflozin	06/12	PU
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA	28/11	AQ
Daewoong Pharmaceutical : announces ‘3E Global Hyper-Competitive Strategy' at CPHI 2023... Aiming for USD 745M in novel drug sales by 2030	26/23/26	PU
Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market	19/23/19	AQ
Daewoong Pharmaceutical : Initiates Global Export of 'Novel Drug'...Launches 'Fexuprazan' in the Philippines	17/23/17	PU
Daewoong Pharmaceutical : Reports Second Quarter 2023 Financial Results	27/23/27	PU
Vincere Biosciences announces strategic investment from Daewoong Pharmaceutical and HanAll Biopharma to foster collaboration	13/23/13	AQ
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson's disease	13/23/13	AQ
Daewoong Pharmaceutical : reaches sales of KRW292.3 billion and business profits of KRW31 billion in the first quarter…	03/23/03	PU
Daewoong Pharmaceutical : announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio	28/23/28	PU
Daewoong pharmaceutical : ‘Envlo’ of Daewoong Pharmaceutical, to be launched in the global markets... Entering the 1.54 billion USD Market in Brazil and Mexico	24/23/24	PU
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea	26/23/26	AQ
Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates	04/23/04	AQ
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update	01/22/01	AQ
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative	12/22/12	AQ
HanAll Biopharma Reports Full-Year 2021 Results and Provides Business Update	24/22/24	AQ
HanAll Biopharma Reports Third Quarter 2021 Results	28/21/28	AQ
Evolus : Strengthens Balance Sheet, Secures $40 Million Investment	07/20/07	AQ
Daewoong Pharmaceutical : Unveils Phase 3 Clinical Data of Fexuprazan, A Novel Potassium-competitive Acid Blocker	08/20/08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Daewoong Pharmaceutical Co., Ltd

Equities

A069620

KR7069620003

Press Releases

Filters